SIRPA and ovarian carcinoma: Another phase Ib trial is evaluating MIRV alongside SL-172154, a fusion protein consisting of human signal-regulatory protein alpha (SIRPα) and CD40L linked via a human Fc, in patients with platinum-resistant ovarian cancer (NCT05483933).